Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP187-V2B food-effect pharmacokinetic study in healthy volunteers
NL-OMON46121Phase 1Active, not recruiting
- Sponsor
- Forward Pharma
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FP187-V2B in multiple sclerosis (MS) and psoriasis, sponsored by Forward Pharma. Primary endpoint: Plasma pharmacokinetics of monomethyl fumarate. Started Jun 2016; status: active, not recruiting.
02
Drugs
FP187-V2B
03
Conditions
multiple sclerosis (MS)psoriasis
Beyond the preview
Go deeper on NL-OMON46121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46121.